New drug aims to stop the agonizing itch of dialysis
NCT ID NCT04711603
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 3 trial tested a drug called MR13A9 in 178 adults on hemodialysis who suffer from severe itching (uremic pruritus). The study compared MR13A9 to a placebo to see if it reduces itch intensity, measured by a daily 0-10 rating scale. If successful, MR13A9 could become a new treatment option for this distressing symptom.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MR13A9 (a drug given intravenously)
What this could lead to
If it works, this could provide a new option to reduce severe itching in people on hemodialysis.
What could go wrong
This is a single Phase 3 trial with 178 participants. The drug may not work better than placebo, and long-term safety is still being checked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Multiple Locations, Japan